MedTrace Logo

Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration

NCT02226666 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 107

Last updated 2017-01-13

No results posted yet for this study

Summary

The purpose of this study is to prospectively compare the physiologic response of patients who receive either intravenous gadoxetic acid (Eovist) or intravenous gadobenate dimeglumine (MultiHance).

Conditions

  • Liver Tumor

Interventions

DRUG

MRI with Multihance

Patients will have Multihance used as an IV contrast agent for their scan.

DRUG

MRI with Eovist

Patients will have Eovist used as an IV contrast agent for their scan.

Sponsors & Collaborators

Principal Investigators

  • Matthew Davenport, MD · University of Michigan Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02226666 on ClinicalTrials.gov